- Trials with a EudraCT protocol (1,544)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
1,544 result(s) found for: Standard of practice.
Displaying page 1 of 78.
EudraCT Number: 2004-001941-14 | Sponsor Protocol Number: AB1 | Start Date*: 2006-05-15 |
Sponsor Name:NHS TAYSIDE | ||
Full Title: MECHANISMS OF IMIQUIMOD INDUCED REGESSION IN LENTIGO MALIGNA | ||
Medical condition: lentigo maligna | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001417-33 | Sponsor Protocol Number: 20040156 | Start Date*: 2004-10-19 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy | |||||||||||||
Medical condition: Chemotherapy induced anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) FI (Completed) AT (Completed) CZ (Completed) GB (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006148-69 | Sponsor Protocol Number: AIC001-2-001 | Start Date*: 2007-03-06 |
Sponsor Name:AiCuris GmbH & Co. KG | ||
Full Title: Phase 2a Randomized, Controlled, Multi-center, Open-label Dose Ranging Proof of Concept Study to Evaluate the Safety, Tolerability and Antiviral Activity of AIC-001 Over 14 Days of Dosing in Patien... | ||
Medical condition: Pre-emptive treatment for Human cytomegalovirus (HCMV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002104-12 | Sponsor Protocol Number: FP2CLI004 | Start Date*: 2021-09-08 | |||||||||||
Sponsor Name:Faron Pharmaceuticals Ltd. | |||||||||||||
Full Title: A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelody... | |||||||||||||
Medical condition: -Myelodysplastic Syndrome -Chronic Myelomonocytic Leukemia -Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002076-41 | Sponsor Protocol Number: C16019 | Start Date*: 2014-06-17 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant | |||||||||||||
Medical condition: Newly diagnosed multiple myeloma (NDMM) following induction therapy and autologous stem cell transplant (ASCT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) SE (Completed) DK (Completed) IT (Completed) PT (Completed) ES (Completed) AT (Completed) HU (Completed) DE (Completed) NL (Completed) GR (Completed) PL (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001306-35 | Sponsor Protocol Number: APHP200394 | Start Date*: 2020-04-05 |
Sponsor Name:DRCI APHP | ||
Full Title: Protective role of inhaled steroids for COVID-19 infection | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001394-13 | Sponsor Protocol Number: C16021 | Start Date*: 2015-08-12 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell... | |||||||||||||
Medical condition: Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) DK (Completed) ES (Completed) SE (Completed) HU (Completed) FR (Completed) HR (Prematurely Ended) PL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011309-18 | Sponsor Protocol Number: R096769PRE4001 | Start Date*: 2009-12-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care | |||||||||||||
Medical condition: premature ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003258-25 | Sponsor Protocol Number: X16120 | Start Date*: 2019-07-04 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Bone Study Bone Healing During Ninlaro Exposure. An open label phase 2 single centre clinical trial | |||||||||||||
Medical condition: multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001008-13 | Sponsor Protocol Number: SUPERIOR | Start Date*: 2018-07-09 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: A SUPAR GUIDED DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF INITIATION OF ANTIBIOTICS FOR PRESUMED INFECTION AT THE EMERGENCY DEPARTMENT: THE SUPERIOR TRIAL | |||||||||||||
Medical condition: Α suPAR guided early antibiotic administration at the Emergency Room for presumed infection and sepsis and evaluation of the impact of this intervention to the patients’ final outcome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002141-11 | Sponsor Protocol Number: Vedolizumab-3035 | Start Date*: 2018-11-08 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Und... | |||||||||||||
Medical condition: Intestinal acute graft-versus-host disease (aGvHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) DE (Completed) AT (Completed) PL (Completed) ES (Completed) PT (Completed) BE (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005496-17 | Sponsor Protocol Number: C16010 | Start Date*: 2012-10-10 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed ... | |||||||||||||
Medical condition: Relapsed and/or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PT (Completed) AT (Completed) ES (Restarted) CZ (Completed) SE (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005410-21 | Sponsor Protocol Number: RAE03 | Start Date*: 2006-04-20 |
Sponsor Name:Bradford Teaching Hospitals NHS Foundation Trust | ||
Full Title: Improving the Patient's Experience of a Bone Marrow Biopsy - An evidence based approach to service improvement. | ||
Medical condition: Procedural pain experienced during bone marrow biopsy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005474-77 | Sponsor Protocol Number: AGO/2005/004 | Start Date*: 2005-12-13 |
Sponsor Name:University Hospital Ghent | ||
Full Title: Validation of a pharmacologic profile of propofol | ||
Medical condition: Anesthesia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001173-96 | Sponsor Protocol Number: PHOTOSTENT-02 | Start Date*: 2005-10-26 |
Sponsor Name:University College London | ||
Full Title: Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised, phas... | ||
Medical condition: Advanced or metastatic cholangiocarcinomas and other biliary tract tumours | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002089-11 | Sponsor Protocol Number: CMBG453B12301 | Start Date*: 2020-06-23 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla... | ||||||||||||||||||
Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) FI (Prematurely Ended) LT (Completed) NL (Prematurely Ended) GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002311-39 | Sponsor Protocol Number: 101069207 | Start Date*: 2022-09-07 |
Sponsor Name:University Of Cyprus | ||
Full Title: Phase II trial for the use of ketotifen to enhance therapy in patients with sarcoma receiving standard chemotherapy | ||
Medical condition: Patients with sarcoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CY (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000052-38 | Sponsor Protocol Number: FOSFO3GCRE | Start Date*: 2023-06-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: Intravenous Fosfomycin in hospitalized patients with complicated urinary tract infections due to Third-generation cephalosporinresistant Enterobacterales. | |||||||||||||
Medical condition: urinary tract infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004625-14 | Sponsor Protocol Number: 1230.28 | Start Date*: 2016-07-05 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy ... | ||
Medical condition: Paediatric AML after first-line failure | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) CZ (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-001183-31 | Sponsor Protocol Number: MT18328 | Start Date*: 2005-10-20 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a... | ||
Medical condition: Heart Transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) AT (Completed) CZ (Completed) GB (Completed) BE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
